ライフサイエンスコーパス: neurofibroma

1 stature, [4] tibial bone curvature, and [5] neurofibroma.

2 yeloid leukemia, optic glioma, and plexiform neurofibroma.

3 e NF1 and a clinically significant plexiform neurofibroma.

4 ated a patient with a debilitating plexiform neurofibroma.

5 atient with a nonresectable and debilitating neurofibroma.

6 back 11 years previously and diagnosed as a neurofibroma.

7 The most common types include schwannoma and neurofibroma.

8 e expression and tumor macrophage numbers in neurofibroma.

9 and fibroblastoid cells derived from an NF1 neurofibroma.

10 xpression of many cytokines overexpressed in neurofibroma.

11 l as in the MPNST precursor lesion plexiform neurofibroma.

12 se model of neurofibromatosis type 1-related neurofibroma.

13 measure the change in size of the plexiform neurofibroma.

14 s, suggesting that these sarcomas arise from neurofibromas.

15 s for children with orbitotemporal plexiform neurofibromas.

16 o demonstrated ciliary body involvement with neurofibromas.

17 arly relevant to medical management of these neurofibromas.

18 traits to predict the presence of paraspinal neurofibromas.

19 gain in Nf1(+/-) mast cell degranulation in neurofibromas.

20 over-expressed in MPNST compared with benign neurofibromas.

21 monitor for the malignant transformation of neurofibromas.

22 order characterized by complex tumors called neurofibromas.

23 ait spots, skinfold freckling, and cutaneous neurofibromas.

24 synthesize excessive collagen, a hallmark of neurofibromas.

25 eurofibromas or clinically obvious plexiform neurofibromas.

26 fibromatosis type 1 (NF1) -related plexiform neurofibromas.

27 heral nerve sheath tumors (MPNST) and benign neurofibromas.

28 and the S100(+) cells from each of 9 benign neurofibromas.

29 causes abnormalities characteristic of human neurofibromas.

30 ed in 11 MPNST samples from 8 patients and 7 neurofibromas.

31 ficantly altered cytokine gene expression in neurofibromas.

32 SCs and SCP in the context of mice that form neurofibromas.

33 aspinal plexiform neurofibromas and atypical neurofibromas.

34 elop benign Schwann cell (SC) tumours called neurofibromas.

35 X1 protein overexpression in human plexiform neurofibromas.

36 ity of specific cell type that gives rise to neurofibromas.

37 kt expression in grade 3 PNSTs compared with neurofibromas.

38 schwannomas, 2 of 2 medulloblastomas, 1 of 1 neurofibroma, 1 of 2 neuronoglial tumors, 2 of 3 ependym

39 Plexiform neurofibroma, a benign peripheral nerve tumor, is associ

40 erized by the development of numerous benign neurofibromas, a small subset of which progress to malig

41 ng by methylation were not identified in the neurofibromas analyzed.

42 axon-glial interactions, characteristics of neurofibroma and are hypoalgesic.

43 Schwann cells had a significant increase in neurofibroma and grade 3 PNST (MPNST) formation compared

44 the cell of origin for murine Nf1 plexiform neurofibroma and leverage this finding to develop a plat

45 n useful for identifying novel genes driving neurofibroma and MPNST pathogenesis.

46 nt reduced aberrantly proliferating cells in neurofibroma and MPNST, prolonged survival of mice impla

47 Common insertion site (CIS) analysis of 269 neurofibromas and 106 MPNSTs identified 695 and 87 sites

48 roblasts are a major cellular constituent in neurofibromas and are a source of collagen that constitu

49 Arf loss and identified paraspinal plexiform neurofibromas and atypical neurofibromas.

50 ncreased senescence observed in human benign neurofibromas and colon adenoma lesions in vivo.

51 sociated plexiform neurofibromas or atypical neurofibromas and grew rapidly on transplantation.

52 e are intriguing links between the growth of neurofibromas and levels of circulating hormones: neurof

53 matosis type 1 (NF1) patients develop benign neurofibromas and malignant peripheral nerve sheath tumo

54 disorder of the nervous system resulting in neurofibromas and malignant peripheral nerve sheath tumo

55 ts are predisposed to certain tumors such as neurofibromas and may associate with vascular disorder.

56 eas loss in adulthood caused large plexiform neurofibromas and morbidity beginning 4 months after ons

57 activation was sustained in mouse and human neurofibromas and MPNST.

58 es transcriptome analyses of mouse and human neurofibromas and MPNSTs and identified global negative

59 nd may be an important therapeutic target in neurofibromas and MPNSTs.

60 Neurofibromas and optic pathway gliomas result from NF1

61 elopment of nervous system tumors, including neurofibromas and pilocytic astrocytomas.

62 Neurofibromas and schwannomas are benign peripheral nerv

63 Neurofibromas and schwannomas are benign Schwann cell-de

64 clinical characteristics and pathogenesis of neurofibromas and schwannomas in the neurofibromatoses.

65 Several cases of multiple isolated neurofibromas and spinal neurofibromas were reported.

66 Major superficial plexiform neurofibromas and symptomatic spinal neurofibromas were

67 f the disease are multiple and severe due to neurofibromas and their occasional malignant transformat

68 response rate among patients with plexiform neurofibromas and to assess clinical benefit.

69 ncisional biopsy confirmed the presence of a neurofibroma, and because of the extent of the lesion, t

70 sitive Schwann cells of dermal and plexiform neurofibromas, and in endothelial cells of tumor blood v

71 Macrophages are abundant in neurofibromas, and macrophage targeted interventions may

72 uch as schwannomatosis and multiple isolated neurofibromas, and malignant peripheral nerve sheath tum

73 e prone to optic gliomas, malignant gliomas, neurofibromas, and malignant peripheral nerve sheath tum

74 ibroblasts, and tumor Schwann cells of skin, neurofibromas, and MPNSTs.

75 ipheral nerve sheath tumors (MPNSTs), benign neurofibromas, and normal Schwann cells.

76 Plexiform neurofibromas are a hallmark of NF1 and result from loss

77 Benign peripheral nerve tumors called neurofibromas are a major source of morbidity for patien

78 Plexiform neurofibromas are benign nerve sheath Schwann cell tumor

79 Neurofibromas are benign peripheral nerve tumors driven

80 Neurofibromas are benign tumors comprised primarily of S

81 Neurofibromas are benign tumors of the peripheral nerve

82 OPGs and orbitofacial neurofibromas are clinically diverse.

83 Plexiform neurofibromas are common NF1 tumors carrying a risk of m

84 Neurofibromas are common tumors found in neurofibromatos

85 Neurofibromas are complex tumors and composed mainly of

86 Neurofibromas are complex tumors composed of axonal proc

87 Neurofibromas are highly vascularized, and recent studie

88 Plexiform neurofibromas are one of the most common tumors encounte

89 Plexiform neurofibromas are pathognomonic of the disease and consi

90 Plexiform neurofibromas are peripheral nerve sheath tumors initiat

91 Dermal and plexiform neurofibromas are peripheral nerve sheath tumors that ar

92 Plexiform neurofibromas are slow growing benign tumors that are hi

93 Plexiform neurofibromas are slow-growing chemoradiotherapy-resista

94 ay gliomas (OPGs) and orbitofacial plexiform neurofibromas are two of the more common ophthalmic mani

95 Neurofibromas arise from the Schwann cell lineage follow

96 Multiple pharmaceuticals have shown neurofibroma arrest in vitro and are in phase II clinica

97 Dermal and plexiform neurofibromas as well as malignant peripheral nerve shea

98 uding the use of MEK inhibitors in plexiform neurofibromas associated with neurofibromatosis type 1 a

99 se Schwann cell progenitors (SCPs) and mouse neurofibromas at the messenger RNA and protein levels.

100 rotein profiling, and show that treatment of neurofibroma-bearing mice with polyethylene glycolyated

101 ove survival or reduce macrophage numbers in neurofibroma-bearing mice.

102 elieved to be the primary pathogenic cell in neurofibromas because they harbor biallelic neurofibromi

103 fibromatosis type 1 and inoperable plexiform neurofibromas benefited from long-term dose-adjusted tre

104 Patients commonly present with plexiform neurofibromas, benign but debilitating growths that can

105 ral nerve sheath tumors (MPNSTs) from benign neurofibromas (BNFs) in patients with neurofibromatosis

106 -Ras2/TC21 displayed a delay in formation of neurofibromas but an acceleration in formation of brain

107 sis type 1 (NF1) patients are predisposed to neurofibromas but the driver(s) that contribute to neuro

108 We validated type-I interferon expression in neurofibroma by protein profiling, and show that treatme

109 tablished from 10 dermal and eight plexiform neurofibromas by selective subculture using glial growth

110 Neurofibromas can cause extensive destruction of alveola

111 demonstrate that fibro-blasts isolated from neurofibromas carried at least one normal NF1 allele and

112 lignant transformation of internal plexiform neurofibromas carries a poor prognosis, in part because

113 To determine which neurofibroma cell type has altered Ras-GTP regulation, w

114 In dissociated neurofibroma cells from NF1 patients, Ras-GTP was elevat

115 Consistently, knockdown of KANK1 in neurofibroma cells promoted cell growth.

116 signaling results in development of multiple neurofibromas, complex tumors of the peripheral nerves.

117 1 patients develop peripheral nerve tumors (neurofibromas) composed mainly of Schwann cells and fibr

118 odels have shed light on the pathogenesis of neurofibromas confirming that the Schwann cell initiates

119 Neurofibromas contained cells with Remak bundle disrupti

120 s to develop benign peripheral nerve tumors (neurofibromas) containing Schwann cells (SCs).

121 timulate the growth of human endothelial and neurofibroma-derived cells.

122 f neurofibromin-deficient ECs in response to neurofibroma-derived growth factors both in vitro and in

123 mplete loss of Pten dramatically accelerated neurofibroma development and led to the development of h

124 This paradigm is relevant to understanding neurofibroma development in neurofibromatosis type I pat

125 fic mutation to the suppression of cutaneous neurofibroma development is unknown.

126 rstanding early cellular events that dictate neurofibroma development, as well as for the development

127 is necessary but not sufficient to initiate neurofibroma development.

128 sis, asserting that tumorigenic cells in the neurofibroma do not arise and grow in isolation.

129 s present in approximately half of the total neurofibromas examined.

130 xpressed PR, whereas only a minority (5%) of neurofibromas expressed estrogen receptor.

131 The majority (75%) of neurofibromas expressed PR, whereas only a minority (5%)

132 of the Schwann cell lineage can give rise to neurofibromas following loss of NF1.

133 We examined 59 human neurofibromas for the expression of estrogen and progest

134 loss of heterozygosity is not sufficient for neurofibroma formation and Nf1 haploinsufficiency in at

135 neurofibromin-deficient SCs are involved in neurofibroma formation and, by selective subculture, pro

136 ibromas but the driver(s) that contribute to neurofibroma formation are not fully understood.

137 ferent cell types and of elevated Ras-GTP in neurofibroma formation are unclear.

138 Previous studies found that plexiform neurofibroma formation in a mouse model requires biallel

139 Our results raise the possibility that neurofibroma formation in individuals with neurofibromat

140 e approaches to develop therapies to prevent neurofibroma formation in NF1 patients.

141 lls augments angiogenesis, which may promote neurofibroma formation in NF1.Oncogene advance online pu

142 etion of Runx1 in SCs and SCPs delayed mouse neurofibroma formation in vivo.

143 ls that closely recapitulate human plexiform neurofibroma formation indicate that tumorigenesis neces

144 To understand whether neurofibroma formation is possible after birth, we induc

145 In mouse models of plexiform neurofibroma formation, Nf1 haploinsufficient mast cells

146 mbryonic and adult Schwann cells can lead to neurofibroma formation.

147 identify a novel molecular target to inhibit neurofibroma formation.

148 of driving complex changes characteristic of neurofibroma formation.

149 s necessary, but not sufficient, to initiate neurofibroma formation.

150 mast cells that is likely to be important in neurofibroma formation.

151 s confirming that the Schwann cell initiates neurofibroma formation.

152 other neural crest derivatives contribute to neurofibroma formation.

153 Trauma has been proposed to trigger neurofibroma formation.

154 mouse, loss of Nf1 in the SC lineage causes neurofibroma formation.

155 ed the correlation between EGFR activity and neurofibroma formation.

156 tion cells, suggesting RUNX1 might relate to neurofibroma formation.

157 oss of NF1 in Schwann cells drives plexiform neurofibromas formation, additional loss of Ink4a/Arf co

158 al loss of Ink4a/Arf contributes to atypical neurofibromas formation, and further changes underlie tr

159 Upon transplantation, atypical neurofibromas generated genetically engineered mice (GEM

160 cating the hematopoietic system in plexiform neurofibroma genesis, delineate the physiology of stem c

161 a role for the microenvironment in plexiform neurofibroma genesis.

162 t progesterone may play an important role in neurofibroma growth and suggest that antiprogestins may

163 ned Ras/Raf/MEK/ERK signaling contributes to neurofibroma growth in a neurofibromatosis mouse model (

164 e inhibitor of JAK2/STAT3 signaling, reduces neurofibroma growth in mice with conditional, biallelic

165 ole for MK as a mediator of angiogenesis and neurofibroma growth in NF1.

166 fibromatosis type 1 and inoperable plexiform neurofibromas had durable tumor shrinkage and clinical b

167 naling in malignant transformation of benign neurofibromas have been described.

168 ther examine the role of these mutant SCs in neurofibroma histogenesis.

169 ygous for the Nf1 gene promote the growth of neurofibromas in a mouse model of neurofibromatosis and

170 implanted with human MPNST cells, and shrank neurofibromas in more than 80% of mice tested.

171 On occasion, neurofibromas in neurofibromatosis type 1 may be present

172 Neurofibromas in NF1 and schwannomas in NF2 or schwannom

173 Benign plexiform neurofibromas in NF1 patients can transform spontaneousl

174 ved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1.

175 ib mesylate could be used to treat plexiform neurofibromas in patients with NF1.

176 e burden of clinically significant plexiform neurofibromas in patients with NF1.

177 owth is caused by the formation of plexiform neurofibromas in the connective tissue of the gingiva.

178 characterized by the formation of cutaneous neurofibromas infiltrated with a high density of degranu

179 dominant disorder characterized by cutaneous neurofibromas infiltrated with large numbers of mast cel

180 the adult and narrow the range of potential neurofibroma-initiating cell populations.

181 cally, expression of CNP-hEGFR increased SCP/neurofibroma-initiating cell self-renewal, a surrogate f

182 comparison of microarray gene lists on human neurofibroma-initiating cells and developed neurofibroma

183 ing in Nf1+/- hematopoietic cells diminishes neurofibroma initiation and progression.

184 we identified RUNX1 overexpression in human neurofibroma initiation cells, suggesting RUNX1 might re

185 gest that Runx1 has an important role in Nf1 neurofibroma initiation, and inhibition of RUNX1 functio

186 To test if EGFR activity affects neurofibroma initiation, size, and/or number, we studied

187 CP), which have been implicated in plexiform neurofibroma initiation.

188 of tyrosine kinase expression in SCPs modify neurofibroma initiation.

189 Extent of orbitotemporal plexiform neurofibroma involvement was assessed clinically and wit

190 The management of the orbitofacial neurofibroma is primarily surgical, and the systematic s

191 sulted in the development of small plexiform neurofibromas late in life, whereas loss in adulthood ca

192 f scid mice consistently produced persistent neurofibroma-like tumors with diffuse and often extensiv

193 Orbitotemporal plexiform neurofibroma location was classified as isolated eyelid

194 ting STAT3-dependent, local proliferation in neurofibroma macrophage accumulation, and decreased Schw

195 iological approach to targeted therapies for neurofibromas, malignant peripheral nerve sheath tumours

196 of the prevalent heterozygous cells found in neurofibromas, mast cells and fibroblasts interact direc

197 and its relevance as a therapeutic target in neurofibroma, merit further investigation.

198 Thus, the plexiform neurofibroma microenvironment involves a tumor/stromal i

199 cells underpin inflammation in the plexiform neurofibroma microenvironment of neurofibromatosis type

200 hematopoietic contributions to the plexiform neurofibroma microenvironment, and highlight application

201 opoietic cells and their contribution to the neurofibroma microenvironment, and highlight the applica

202 ECs as a potential therapeutic target in the neurofibroma microenvironment.

203 and/or SC proliferation, and that targeting neurofibroma miRs is feasible, and might provide novel t

204 n for these tumors and report a non-germline neurofibroma model for preclinical drug screening to ide

205 f NF1 children with orbitotemporal plexiform neurofibromas, most commonly because of ptosis and aniso

206 mouse model that accurately models plexiform neurofibroma-MPNST progression in humans would facilitat

207 elopment of benign neurofibromas; subsequent neurofibroma-MPNST progression is caused by aberrant gro

208 0)-GGFbeta3 mice represent a robust model of neurofibroma-MPNST progression useful for identifying no

209 er P(0)-GGFbeta3 mice accurately model human neurofibroma-MPNST progression, cohorts of these animals

210 ither externally visible cutaneous/plexiform neurofibromas nor other tumors.

211 Genetic studies demonstrate that in neurofibromas, nullizygous loss of Nf1 in Schwann cells

212 FR mice versus heterozygous littermates, and neurofibroma number and size increased when CNP-hEGFR wa

213 Neurofibroma number increased in homozygous CNP-hEGFR mi

214 ng in Nf1(fl/fl);DhhCre;Wa2/+ mice decreased neurofibroma number.

215 In contrast, neurofibromas occur with high penetrance in mice in whic

216 Neurofibromas occur with high penetrance in mice in whic

217 fibromas and levels of circulating hormones: neurofibromas often first appear around the time of pube

218 al structures (orbital-periorbital plexiform neurofibroma [OPPN]) can result in significant visual lo

219 Paraffin-embedded neurofibroma or MPNST blocks were assembled in a tissue

220 ons affecting genes not previously linked to neurofibroma or MPNST pathogenesis.

221 tained regions of nerve-associated plexiform neurofibromas or atypical neurofibromas and grew rapidly

222 delAAT (p.990delM) mutation but no cutaneous neurofibromas or clinically obvious plexiform neurofibro

223 potential therapeutic treatment strategy for neurofibroma patients.

224 meningiomas, ependymomas, astrocytomas, and neurofibromas), peripheral neuropathy, ophthalmological

225 n genetic disorder characterized by multiple neurofibromas, peripheral nerve tumors containing mainly

226 emi-automated tumor volume maps of plexiform neurofibroma (PN) generated by a deep neural network, co

227 Although plexiform neurofibroma (PN) is thought to represent a benign neopl

228 Plexiform neurofibroma (PN) tumors are a hallmark manifestation of

229 athognomonic finding of NF1 is the plexiform neurofibroma (PN), a benign, likely congenital tumor tha

230 in neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNFs).

231 Plexiform neurofibromas (PNs) involving the eyelid, orbit, periorb

232 Within neurofibromas, PR was expressed by non-neoplastic tumor-

233 These neurofibromas presumably arise from NF1 inactivation in

234 umor microenvironment is sufficient to allow neurofibroma progression in the context of Schwann cell

235 ways are major tumor-suppressive barriers to neurofibroma progression.

236 f1+/- fibroblasts and fibroblasts from human neurofibromas proliferate and synthesize excessive colla

237 type 1 and symptomatic inoperable plexiform neurofibromas received oral selumetinib twice daily at a

238 The most frequent neurofibroma-related symptoms were disfigurement (44 pat

239 c and genetic implications, the diagnosis of neurofibroma requires appropriate medical referral.

240 The development of neurofibromas requires loss of both Nf1 alleles in Schwa

241 We verified that neurofibroma SC conditioned medium contains macrophage c

242 tect full-length neurofibromin in any of the neurofibroma SC cultures, indicating that neurofibromin-

243 wed elevated Ras-GTP, unexpectedly revealing neurofibroma Schwann cell heterogeneity.

244 neurofibroma-initiating cells and developed neurofibroma Schwann cells (SCs) we identified RUNX1 ove

245 Some neurofibroma Schwann cells aberrantly express the epider

246 The functions of STAT3 signaling in neurofibroma Schwann cells and macrophages, and its rele

247 ctivity is detectably increased in only some neurofibroma Schwann cells and suggest that neurofibromi

248 Of the different cell types found in neurofibromas, Schwann cells usually provide between 40

249 as peripheral nervous system tumors such as neurofibromas, schwannomas, and malignant peripheral ner

250 MK was induced in human neurofibromas, schwannomas, and various nervous system t

251 F1) gene mutations lead to increased risk of neurofibromas, schwannomas, low grade, pilocytic optic p

252 Among these, multiple hybrid neurofibromas/schwannomas may also appear, not yet being

253 e 22 in almost half of all cases with hybrid neurofibromas/schwannomas of patients with multiple peri

254 re performed molecular analysis of 22 hybrid neurofibromas/schwannomas using array comparative genomi

255 44% of tumors of tested patients with hybrid neurofibromas/schwannomas.

256 Atypical neurofibromas show additional frequent loss of CDKN2A/In

257 tive measurement of orbitotemporal plexiform neurofibroma size, and larger volumes were associated wi

258 raction inhibitor, Ro5-3335, decreased mouse neurofibroma sphere number in vitro.

259 changes, resulting in development of benign neurofibromas; subsequent neurofibroma-MPNST progression

260 Nascent MPNSTs were identified within neurofibromas, suggesting that these sarcomas arise from

261 kable for an early age at onset of cutaneous neurofibromas, suggesting the deletion of an additional

262 Sixteen MPNSTs but none of the neurofibromas tested were found to have somatic mutation

263 quirement in formation of TGF-beta-dependent neurofibromas that arise in Nf1-deficient mice.

264 al loss results in the development of benign neurofibromas that can progress to malignancy.

265 rapeutic options for patients with plexiform neurofibromas that cannot be surgically removed because

266 atosis type 1 (NF1) develop benign plexiform neurofibromas that frequently progress to become maligna

267 sion and action of NRG-1 in human MPNSTs and neurofibromas, the benign precursor lesions from which M

268 heral nerves might underlie the formation of neurofibromas, the hallmark of neurofibromatosis.

269 oietic effector cells long known to permeate neurofibroma tissue, mediate key mitogenic signals that

270 e gain-in-functions, and mast cells permeate neurofibroma tissue.

271 The genetic evolution from a benign neurofibroma to a malignant sarcoma in patients with neu

272 rophages from wild-type and mutant nerve and neurofibroma to identify candidate pathways involved in

273 fibromatosis type 1 and inoperable plexiform neurofibromas to determine the maximum tolerated dose an

274 luence the multicellular microenvironment of neurofibromas to inhibit the development and/or progress

275 addition, malignant progression of plexiform neurofibromas to malignant peripheral nerve sheath tumor

276 g may contribute to the conversion of benign neurofibromas to MPNSTs.

277 ound that EGFR overexpression promotes mouse neurofibroma transformation to aggressive MPNST (GEM-PNS

278 can rapidly recapitulate the onset of human neurofibroma tumorigenesis and the progression to MPNSTs

279 es with enhanced susceptibility to plexiform neurofibroma tumorigenesis.

280 nts to mast cells as crucial contributors to neurofibroma tumorigenesis.

281 osis, which is characterized by formation of neurofibromas (tumors of peripheral nerves).

282 h NF1 have cutaneous, diffuse, and plexiform neurofibromas, tumors comprised primarily of Schwann cel

283 , 0%-7%) had discrete cutaneous or plexiform neurofibromas, typical NF1 osseous lesions, or symptomat

284 del) boar developed a large diffuse shoulder neurofibroma, visualized on magnetic resonance imaging,

285 hildren (71%) and decreases from baseline in neurofibroma volume in 12 of 18 mice (67%).

286 with amblyopia had orbitotemporal plexiform neurofibroma volumes greater than 10 mL.

287 ia secondary to the orbitotemporal plexiform neurofibroma was present in 13 subjects (62%) and was ca

288 ase from baseline in the volume of plexiform neurofibromas) was monitored by using volumetric magneti

289 Typical immunohistochemical features of neurofibroma were not observed.

290 exiform neurofibromas and symptomatic spinal neurofibromas were more prevalent in these individuals c

291 Uveal neurofibromas were noted in all patients; anteriorly dis

292 f multiple isolated neurofibromas and spinal neurofibromas were reported.

293 Further, NF1 patients develop vascular neurofibromas where tumor vessels are invested in a dens

294 Mast cells infiltrate neurofibromas, where they secrete proteins that can remo

295 f neurofibromatosis type 1-related plexiform neurofibromas, which are characterized by elevated RAS-m

296 The development of neurofibromas, which are complex tumors composed of mult

297 acterized by both malignant and nonmalignant neurofibromas, which are composed of Schwann cells, degr

298 Patients with NF1 develop numerous neurofibromas, which contain many inflammatory mast cell

299 his report, we present the case of a palatal neurofibroma with radiographic involvement in a patient

300 and were necropsied; 94% developed multiple neurofibromas, with 70% carrying smaller numbers of MPNS